Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain training plus drug may ease chemo nerve damage

NCT ID NCT04560673

Ongoing Symptom relief Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining neurofeedback (a brain-wave training therapy) with the drug duloxetine can better relieve nerve pain caused by chemotherapy than either treatment alone. About 336 cancer survivors with persistent nerve pain will be randomly assigned to one of three groups: duloxetine only, neurofeedback only, or both together. The goal is to see if the combination reduces pain unpleasantness and improves quality of life after five weeks of treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
duloxetine and neurofeedback training
What this could lead to
If it works, this could offer a new way to manage nerve pain from chemotherapy without relying solely on medication.
What could go wrong
This is a mid-stage trial with 336 participants, so results are not yet proven. The combination may not be more effective than duloxetine alone, and neurofeedback requires time and commitment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced neuropathy hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM MALIGNANT SOLID NEOPLASM

Contacts and locations

Locations

  • Harris Health System (LBJ)

    Houston, Texas, 77026, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.